IBRX
ImmunityBio, Inc.NASDAQHealthcare$7.30+2.24%ClosedMarket Cap: $7.51B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-14.03
P/S
64.25
EV/EBITDA
-36.09
DCF Value
$-23.84
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.4%
Operating Margin
-226.0%
Net Margin
-310.2%
ROE
64.3%
ROA
-70.0%
ROIC
-56.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $38.3M | 88.9% | $-64.7M | $-61.9M | $-0.06 | — |
| FY 2025 | $113.3M | 99.3% | $-256.0M | $-351.4M | $-0.38 | — |
| Q3 2025 | $32.1M | 87.1% | $-55.6M | $-67.3M | $-0.07 | — |
| Q2 2025 | $26.4M | 99.5% | $-71.3M | $-92.6M | $-0.10 | — |
| Q1 2025 | $16.5M | 99.6% | $-64.4M | $-129.6M | $-0.15 | — |
| Q4 2024 | $7.6M | 100.0% | $-69.4M | $-59.2M | $-0.09 | — |
| FY 2024 | $14.7M | 100.0% | $-344.2M | $-413.6M | $-0.62 | — |
| Q3 2024 | $6.1M | 100.0% | $-80.3M | $-85.7M | $-0.12 | — |
| Q2 2024 | $1.0M | 100.0% | $-99.3M | $-134.6M | $-0.20 | — |
| Q1 2024 | $40.0K | 100.0% | $-95.2M | $-134.1M | $-0.20 | — |
| Q4 2023 | $139.0K | 100.0% | $-85.4M | $-233.4M | $-0.40 | — |
| FY 2023 | $622.0K | 100.0% | $-362.3M | $-583.2M | $-1.15 | — |